Allergy Frontiers, Volume 5: Therapy and Prevention
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs. -
Pharmaceutical Appendix to the Harmonized Tariff Schedule
Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. -
(12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S. -
General Pharmacology
GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC -
Pharmaceutical Appendix to the Harmonized Tariff Schedule
Harmonized Tariff Schedule of the United States Basic Revision 2 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 2 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. -
Bäumer Et Al., 2002
Aus dem Institut für Pharmakologie, Toxikologie und Pharmazie der Stiftung Tierärztliche Hochschule Hannover Phosphodiesterase-4-Inhibitoren zur Behandlung allergischer Hauterkrankungen bei Mensch und Tier Habilitationsschrift zur Erlangung der Venia legendi an der Stiftung Tierärztliche Hochschule Hannover vorgelegt von Dr. med. vet. Wolfgang Bäumer Hannover 2006 2 Inhaltsverzeichnis Seite Liste der Publikationen, die Bestandteil der Habilitationsschrift sind 4 Abkürzungsverzeichnis und Glossar 6 1 Einleitung 10 Allergische Hauterkrankungen bei Mensch und Tier 10 Pharmakotherapie allergischer Hauterkrankungen bei Mensch und Tier 16 Phosphodiesterase-4-Inhibitoren (PDE4-Inhibitoren) 20 2 Fragestellungen der vorliegenden Untersuchungen 27 Sind PDE4-Inhibitoren in Modellen allergischer Entzündungen wirksam? 27 Wirken PDE4-Inhibitoren in Th1/Th2-dominierten Entzündungsgeschehen unterschiedlich? 27 Wird die Funktion von Keratinozyten durch PDE4-Inhibitoren beeinflusst? 27 Wird die Funktion dendritischer Zellen durch PDE4-Inhibitoren beeinflusst? 28 3 Zusammenfassende Darstellung der Ergebnisse und gemeinsame Diskussion 29 3.1 Effekte von PDE4-Inhibitoren in Modellen allergischer Hauterkrankungen 29 3.2 Pharmakologische Beeinflussung caniner, muriner und humaner Keratinozyten durch PDE4-Inhibitoren 38 3.3 Rolle und pharmakologische Beeinflussung dendritischer Zellen in Modellen allergischer Hauterkrankungen 39 3.4 Vergleich der pharmakologischen Wirkung von Glucocorticoiden und PDE4-Inhibitoren 46 3.5 Übertragbarkeit tierexperimenteller Ergebnisse -
(12) United States Patent (10) Patent No.: US 6,333,354 B1 Schudt (45) Date of Patent: Dec
USOO6333354B1 (12) United States Patent (10) Patent No.: US 6,333,354 B1 Schudt (45) Date of Patent: Dec. 25, 2001 (54) SYNERGISTIC COMBINATION OF PDE Buerke et al.: “Synergistic platelet inhibitory effect of the INHIBITORS AND ADENYLATE CYCLASE phosphodiesterase inhibitor piroximone and iloprost: Pros AGONSTS OR GUANYL CYCLYSE taglandins in the Cardiovascular System, 1992, 37/suppl. AGONSTS (71–77).* (75) Inventor: Christian Schudt, Constance (DE) O'Grady et al. “A chemically stable analot 9-beta methyl carbacyclin with Similar effects to epoprostenol proStacyclin (73) Assignee: Byk Gulden Lomberg Chemische prostaglandin in I-2 in man” Br J Clin Pharmacol, 18(6). Fabrik GmbH, Constance (DE) 1984 (921-934).* (*) Notice: Subject to any disclaimer, the term of this Crutchley et al. “Effects of Prostacyclin Analogs on the patent is extended or adjusted under 35 Synthesis of Tissue Factor, Tumor Necrosis Facotr-alpha U.S.C. 154(b) by 0 days. and Interleukin-1beta in Human Monocytic THP-1 Cells”, J Pharmacol and Experimental Therapeutics, 271 (1). 1994. (21) Appl. No.: 09/367,850 446-451. (22) PCT Filed: Feb. 24, 1998 Crutchley et al. “Prostacyclin Analogues Inhibit Tissue (86) PCT No.: PCT/EP98/O1047 Factor Expression in the Human Monocytic Cell Line THP-1 Via a Cyclic AMP-Dependent Mechanism” Arterio S371 Date: Aug. 27, 1999 scler. Thromb, 12(6), 1992. 664-670.* S 102(e) Date: Aug. 27, 1999 Turner et al., Br. J. Pharmacol., “Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the (87) PCT Pub. No.: WO98/37894 anaesthetized guinea-pig", (1994), 111, pp. -
Selective Phosphodiesterase 4 Inhibitors
Journal of Scientific & Indu strial Research Vol. 62, June 2003, pp 537-553 Selective Phosphodiesterase 4 Inhibitors - Emerging Trends in Astluna Therapy (Antiasthmatics-3) Ranju Gupta*, Oeepika Gandhi and Oharam Paul Jindal University In stitute of Pharmaceuti cal Sciences, Panjab Universit y, Chandigarh 160014 Considerable interest has been generated in th e potential utility of isozyme selective inhibitors of phosph odiesterases in the treatment of asthma and other inflali1matory disorders. Heterogeneity in ti ssue distribution as well as their different fun cti onal roles make these enzymes very attractive targets for medicinal chemi sts. To date at least II different fami lies of POE isozymes are known, among which POE 4 plays a major rol e in mod ul ating the activity of virtu ally all cell s involved in the inflammatory process. In hibitors of thi s enzyme family display impressive antiasthmatic ac ti vity by red ucing th e bronchial smooth mu scle tone and consid erable anti-inflammatory activity. The review details th e various classes of POE 4 inhibitors stru cturall y related to rolipram, nitraquazone and xa nthines, which appear to be very attractive models for synthesis of novel selecti ve POE 4 inhibitors potentially useful for the treatment of asthma and chronic obstructive pulmonary di seases. Rationale for the use of POE4 inhibitors in th e treatment of asthma is also discussed. Key words: Phosphodiesterase 4 inhibitors, Asthma therapy, Antiasthmatics, Isozyme, Rol ipram, Nitraquazonc. Xanthincs. Introduction Phosphodiesterase Superfamily There has been growing interest in recent years At least e leven different fami li es of POE tn the utility of selective phosphodiesterase (POE) isozymes are known based on the ir substrate inhibitors as novel targets for drug d iscovery. -
PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE -
Rôle De La Phosphodiestérase Spécifique De L'ampc (PDE4) Dans
Faculté de pharmacie UMR-CNRS 7213 laboratoire de Biophotonique et de pharmacologie, Université de Strasbourg Département de Physiologie et Biophysique, Université de Sherbrooke Rôle de la pho sphodiestérase spécifique de l’AMPc (PDE4) dans deux modèles d’inflammation chronique : le lupus érythémateux disséminé et l’asthme . Thèse présentée à Ecole Doctorale des Sciences de la Vie et de la Santé de Strasbourg en vue de l’obtention du grade de docteur es science en pharmacologie moléculaire, et à la Faculté de médecine et des sciences de la santé en vue de l’obtention du grade de Philosophiae Doctor (Ph.D.) en Physiologie Par YOUGBARE Issaka 20 Décembre 2010 Composition du Jury : Présidente du Jury : Pr Valérie SCHINI-KERTH, Université de Strasbourg, France Rapporteurs externes : Pr Jean- Pierre SAVINEAU, Université Victor Ségalen Bordeaux 2, France Pr Manuel-Campos TOIMIL, Universidade de Santiago de Compostela, Espagne Co-directeurs de thèses : Dr Claire LUGNIER, co-directeur de thèse, Université de Strasbourg, France Pr Eric ROUSSEAU, Co-directeur de thèse, Université de Sherbrooke, Canada SOMMAIRE REMERCIEMENTS ................................................................................................................ 5 Listes des Manuscrits pour publications ................................................................................ 6 Listes des Communications à des congrès internationaux ................................................... 6 Liste des abréviations .............................................................................................................. -
Stembook 2018.Pdf
The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.